Cargando…
1588P SARS-CoV-2 antibody seroprevalence and safety of vaccines in cancer patients who recovered from COVID-19
Autores principales: | Patel, M., Felip, E., Sharkey, R., Krengli, M., Chester, J.D., Sita-Lumsden, A., Mukherjee, U., Russell, B., Loizidou, A., Colomba, J., Cruz, C. Andrea, Cabirta, A., Camps, I. Ruiz, Brunet, J., Sureda, A., Patriarca, A., Tondini, C., Pinato, D.J., Cortellini, A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Society for Medical Oncology. Published by Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8454348/ http://dx.doi.org/10.1016/j.annonc.2021.08.1581 |
Ejemplares similares
-
La gran Armada, 1588 /
por: Martin, Colin, 1939-
Publicado: (1988) -
PReS13-SPK-1588: Recurrent fevers
por: Frenkel, J
Publicado: (2013) -
319O The systemic pro-inflammatory response identifies cancer patients with adverse outcomes from SARS-CoV-2 infection
por: Dettorre, G., et al.
Publicado: (2020) -
Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study
por: Pinato, David J, et al.
Publicado: (2021) -
P1588: A SINGLE CENTER COMPARATIVE CLINICAL ANALYSIS OF THE SARS-COV-2 INFECTION BEFORE AND AFTER VACCINATION IN PATIENTS DIAGNOSED WITH HEMATOLOGIC MALIGNANCIES
por: Jiménez, M., et al.
Publicado: (2022)